Federico Hinestrosa, MD, FACP, FIDSA

Associate Medical Director

Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic.
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting.
Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Severe gastroenteritis and hypovolemic shock caused by Grimontia (Vibrio) hollisae infection.
Propionibacterium acnes as a cause of prosthetic valve aortic root abscess.

Dr. Hinestrosa received his medical degree in 1997, from the Universidad CES in Medellin, Colombia. He completed his Internal Medicine training at Geisinger Medical Center in Danville Pennsylvania and his Infectious Disease Fellowship at Washington Hospital Center/Georgetown University in Washington DC. He is a certified HIV Specialist through the American Academy of HIV Medicine (AAHIVM)

Dr. Hinestrosa is Board-certified in internal medicine and infectious diseases by the American Board of Internal Medicine. Dr. Hinestrosa became a Fellow of the American College of Physicians. Before joining the Orlando Immunology Center in 2009, Dr. Hinestrosa was an HIV/AIDS Primary Care Consultant at Andromeda Transcultural Health in Washington, DC.

Dr. Hinestrosa was named the Associate Medical Director of OIC in 2017. Besides his clinical duties at OIC, he also plays investigatory roles on the Orlando Immunology Center’s HCV and HIV clinical trials. Dr. Hinestrosa is a member of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine. He has contributed original articles to the medical literature, and has presented abstracts at professional society annual meetings, including the American Association for the Study of Liver Diseases and European Association for the Study of the Liver.

Federico Hinestrosa, MD, FACP, FIDSA

Primary and Sexual Healthcare for All.